Cyxone appoints Cornel Pater as new Chief Medical Officer

Cyxone today announced that Cornel Pater has been appointed as the company’s new Chief Medical Officer (CMO). Most recently, he held the position as Global Medical Director of Clinical Development at Novartis Pharma. As CMO, Cornel Pater is part of Cyxone’s executive management and will play an important role in the continued development of the company’s projects. He joined the company on August 31, 2021.

“I am glad to welcome Cornel Pater to Cyxone. As Chief Medical Officer, his comprehensive knowledge and experience from leading pharmaceutical development projects and coordinating global clinical studies including experience with rheumatoid arthritis and multiple sclerosis studies will be of immense value to the continued development of our drug candidates,” comments Tara Heitner, CEO, Cyxone.

Cornel Pater is a board-certified physician in internal medicine and cardiology and holds a master’s degree in clinical epidemiology from the University of Rotterdam as well as a master’s degree in public health from the National School for Public Health in Utrecht. He has more than 20 years of experience in clinical pharmaceutical development from global key positions at companies such as Affibody, Takeda and Sandoz. Most recently, he has held roles as Global Medical Director Clinical Development at Novartis and as a consultant to several Swedish and Swiss pharmaceutical companies developing Covid-19-therapeutics. He has an extensive background as project leader within development of pharmaceuticals as well as medical technology products, ranging from designing preclinical and clinical trials and submission of regulatory trial applications to reporting clinical trial results and market launch of approved drugs. Cornel Pater joined Cyxone on August 31, 2021.

“I look forward to joining Cyxone at this exciting time and contribute to shaping the clinical development of both Rabeximod and T20K, two innovative candidate drugs addressing still huge unmet medical needs within large therapeutic areas,” says Cornel Pater, new Chief Medical Officer, Cyxone.

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com